Financhill
Sell
41

NONOF Quote, Financials, Valuation and Earnings

Last price:
$63.33
Seasonality move :
4.38%
Day range:
$66.00 - $71.64
52-week range:
$55.28 - $149.55
Dividend yield:
2.52%
P/E ratio:
20.10x
P/S ratio:
7.00x
P/B ratio:
14.64x
Volume:
56.5K
Avg. volume:
123.4K
1-year change:
-46.88%
Market cap:
$293B
Revenue:
$42.1B
EPS (TTM):
$3.28

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NONOF
Novo Nordisk AS
$11.8B -- 21.52% -- --
ASND
Ascendis Pharma AS
$107.9M -$1.71 294.94% -25.18% $222.60
GLTO
Galecto
-- -$2.82 -- -51.46% $8.00
GMAB
Genmab AS
$759.6M $0.23 24.64% -15.88% $29.50
LLY
Eli Lilly and
$12.7B $3.46 26.74% 68.13% $981.63
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NONOF
Novo Nordisk AS
$66.00 -- $293B 20.10x $1.14 2.52% 7.00x
ASND
Ascendis Pharma AS
$160.99 $222.60 $9.7B -- $0.00 0% 23.98x
GLTO
Galecto
$2.70 $8.00 $3.6M -- $0.00 0% --
GMAB
Genmab AS
$20.60 $29.50 $13.1B 11.76x $0.00 0% 4.27x
LLY
Eli Lilly and
$776.72 $981.63 $697.3B 63.20x $1.50 0.7% 14.32x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NONOF
Novo Nordisk AS
40.09% 1.869 3.51% 0.52x
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
GLTO
Galecto
-- 1.269 -- --
GMAB
Genmab AS
-- 0.045 -- 5.24x
LLY
Eli Lilly and
70.96% 0.813 5.19% 0.57x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NONOF
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M
ASND
Ascendis Pharma AS
$87.8M -$109.7M -59.13% -880.05% -48.32% -$90.9M
GLTO
Galecto
-- -$7.1M -- -- -- -$4.9M
GMAB
Genmab AS
$872.2M $313.1M 23.85% 23.85% 56.76% $353M
LLY
Eli Lilly and
$10.5B $5.4B 24.21% 78.25% 29.07% -$1.6B

Novo Nordisk AS vs. Competitors

  • Which has Higher Returns NONOF or ASND?

    Ascendis Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -93.73%. Novo Nordisk AS's return on equity of 86.85% beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.8% $0.91 $33.4B
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About NONOF or ASND?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.23%. On the other hand Ascendis Pharma AS has an analysts' consensus of $222.60 which suggests that it could grow by 38.27%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is NONOF or ASND More Risky?

    Novo Nordisk AS has a beta of 0.660, which suggesting that the stock is 33.959% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock NONOF or ASND?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.52%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or ASND?

    Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Ascendis Pharma AS quarterly revenues of $106.2M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.10x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 7.00x versus 23.98x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    7.00x 20.10x $12.2B $4B
    ASND
    Ascendis Pharma AS
    23.98x -- $106.2M -$99.6M
  • Which has Higher Returns NONOF or GLTO?

    Galecto has a net margin of 32.95% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 86.85% beat Galecto's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.8% $0.91 $33.4B
    GLTO
    Galecto
    -- -$5.23 --
  • What do Analysts Say About NONOF or GLTO?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.23%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 196.19%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GLTO
    Galecto
    1 1 0
  • Is NONOF or GLTO More Risky?

    Novo Nordisk AS has a beta of 0.660, which suggesting that the stock is 33.959% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NONOF or GLTO?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.52%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GLTO?

    Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Galecto's net income of -$6.7M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.10x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 7.00x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    7.00x 20.10x $12.2B $4B
    GLTO
    Galecto
    -- -- -- -$6.7M
  • Which has Higher Returns NONOF or GMAB?

    Genmab AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 59.7%. Novo Nordisk AS's return on equity of 86.85% beat Genmab AS's return on equity of 23.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.8% $0.91 $33.4B
    GMAB
    Genmab AS
    94.77% $0.85 $5.1B
  • What do Analysts Say About NONOF or GMAB?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.23%. On the other hand Genmab AS has an analysts' consensus of $29.50 which suggests that it could grow by 43.2%. Given that Novo Nordisk AS has higher upside potential than Genmab AS, analysts believe Novo Nordisk AS is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    GMAB
    Genmab AS
    4 4 0
  • Is NONOF or GMAB More Risky?

    Novo Nordisk AS has a beta of 0.660, which suggesting that the stock is 33.959% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

  • Which is a Better Dividend Stock NONOF or GMAB?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.52%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or GMAB?

    Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Genmab AS quarterly revenues of $920.3M. Novo Nordisk AS's net income of $4B is higher than Genmab AS's net income of $549.4M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.10x while Genmab AS's PE ratio is 11.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 7.00x versus 4.27x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    7.00x 20.10x $12.2B $4B
    GMAB
    Genmab AS
    4.27x 11.76x $920.3M $549.4M
  • Which has Higher Returns NONOF or LLY?

    Eli Lilly and has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 21.68%. Novo Nordisk AS's return on equity of 86.85% beat Eli Lilly and's return on equity of 78.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    NONOF
    Novo Nordisk AS
    84.8% $0.91 $33.4B
    LLY
    Eli Lilly and
    82.53% $3.06 $54.4B
  • What do Analysts Say About NONOF or LLY?

    Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.23%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 26.38%. Given that Novo Nordisk AS has higher upside potential than Eli Lilly and, analysts believe Novo Nordisk AS is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    NONOF
    Novo Nordisk AS
    0 0 0
    LLY
    Eli Lilly and
    15 3 1
  • Is NONOF or LLY More Risky?

    Novo Nordisk AS has a beta of 0.660, which suggesting that the stock is 33.959% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

  • Which is a Better Dividend Stock NONOF or LLY?

    Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.52%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NONOF or LLY?

    Novo Nordisk AS quarterly revenues are $12.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Novo Nordisk AS's net income of $4B is higher than Eli Lilly and's net income of $2.8B. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.10x while Eli Lilly and's PE ratio is 63.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 7.00x versus 14.32x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NONOF
    Novo Nordisk AS
    7.00x 20.10x $12.2B $4B
    LLY
    Eli Lilly and
    14.32x 63.20x $12.7B $2.8B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 15.72% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 5.86% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 2.25% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock